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Results: In 147 patients, subtyping of the mesothelioma and follow-up 
until death or at least 18 months were available. 73 % (108 patients) 
were of the epithelial subtype. Their median survival was 15 months; 
44% survived 18 months, 25% 2 years, and 9 % 3 years. Two patients 
are still alive after 5 years. 14 were staged as Stage IV (i.e. metasta-
ses outside the hemithorax) when included in the study; their median 
survival was 11 months, 2 have survived 2 years, and one is still alive 
at 61 months. 14% had a mixed subtype; their mean survival was 8 
months, 28 % survived 1 year, 19 % 18 months, and none 2 years. For 
the 12 % with sarcomatous subtype, mean survival was 4 months, 11% 
survived 1 year, and there was no 2-year survivor.
Discussion: The survival was considerably better than in most other 
studies. The reason is probably not that the treatment is superior 
but rather a different selection. Traditionally, surgery has been used 
only very sparingly in the Nordic countries; in countries where this 
is performed, patients with the best PS and the lowest stages will be 
selected for surgery. Thus, generally only patients in worse conditions 
will be treated with chemotherapy. This is important to remember when 
surgical results are evaluated. It is also obvious that subtype is more 
important than stage. 
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Background: Thymoma is an uncommon neoplasm that is derived 
from the epithelial cells of the thymus. Carcinogenesis of thymic 
epithelial tumor has not been clear yet. Our previous study showed 
high frequency of p53 protein expression in thymic carcinoma but not 
in thymoma. Recent reports demonstrated that epigenetic inactivation 
of certain tumor suppressor genes by aberrant promoter methylation 
is frequently observed in cancers and that seems to play an important 
role in carcinogenesis. We examined aberrant methylation patterns of 
5 cancer-related genes in 28 thymic epithelial tumors to clarify their 
carcinogenesis. 
Materials and Methods: We examined aberrant methylation of 5 
cancer-related genes (DAP-K, p-16, MGMT, RAR-β and HPP1 genes) 
in 20 thymomas, 7 thymic carcinomas and one thymic carcinoid that 
we resected between 1985 and 2006 in Tokushima University Hospital. 
There were 1 type A, 6 type AB, 8 type B1, 3 type B2, 2 type B3 thmo-
mas, 7 thymic carcinoma and one carcinoid according to World Health 
Organization histologic classiﬁcation. Masaoka’s clinical staging was 9 
cases in stage I, 7 cases in Stage II, 6 cases in stage III, 5 cases in stage 
IV. The genes selected DAP-K, p-16, MGMT, RAR-β and HPP1 genes 
that were previously described as aberrantly methylated in lung car-
cinoma or malignant mesothelioma. Samples were frozen and stored. 
Genomic DNA was subjected to bisulﬁte treatment. PCR ampliﬁcation 
was done with bisulﬁte-treated DNA, using speciﬁc primer sequences 
for the methylated and unmethylated forms of the genes. PCR products 
were loaded on agarose gels.
Results: In thymoma, aberrant methylation was detected in 3 of 13 
(23.1%) for DAP-K, 1 of 14 (7.1 %) for p-16, 1 of 16 (6.3%) for 
MGMT, 1 of 10 (10%) for RAR-β and 1 of 16 (6.3%) for HPP1. Six 
(29%) of 21 thymomas had aberrant methylation of cancer-related 
genes (1 case in type A, 1 case in type AB and 3 cases in type B1) (3 
cases in stage I and 3 cases in stage II). Methylation was 5 cases in one 
gene and one case in 2 genes. On the other hand, in thymic carcinoma, 
aberrant methylation was detected in 2 of 5(40%) for DAP-K, 0 of 6 (0 
%) for p-16, 5 of 7 (71.4%) for MGMT, 0 of 6 (0%) for RAR-β and 3 
of 7 (42.9%) for HPP1. Six (86%) of 7 thymic carcinomas had aberrant 
methylation. Methylation was 3 cases in one gene, 2 cases in 2 genes 
and one case in 3 genes.
Conclusion: Aberrant methylation were more frequent in thymic car-
cinoma (86%) than in thymoma (29%). And half of thymic carcinoma 
had methylation of several genes. In thymoma, methylation of cancer-
related genes was not related to clinical stage.
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Background: Patients with malignant pleural mesothelioma (MPM) 
are rarely diagnosed at their early stages. It is not fully recognized what 
is the earliest event in the development of MPM and how it progresses. 
The aim of this study was to elucidate the early microscopic changes 
of MPMs that were removed surgically and conﬁrmed to be MPM by 
histological and immunohistochemical examination.
Methods: Fourteen cases with MPM who underwent exrapleural pneu-
monectomy between 1995 and 2006 were investigated. We arbitrarily 
deﬁned mesothelioma at early stage as tumor whose thickness was 
equal to or less than 6mm. We used a panel of immunohistochemical 
markers to conﬁrm the diagnosis of mesothelioma. 
Reults: The age of the patients ranged from 40 to 66 and all were 
male. Four were with Stage IB, ﬁve with Stage II, ﬁve with Stage III, 
and one with Stage IV mesothelioma. Seven of these patients were 
designated at early stage according to our deﬁnition. Five cases were 
epithelioid mesothelioma, one was biphasic, and one was sarcomatoid. 
There was pleural cavity between parietal and visceral pleura and the 
surface of the lung looked normal, but both pleura were fused focally 
in some cases. There was no visible nodule in these cases, but white 
ﬂat maculae or small yellow nodules were observed at the surface of 
the pleura in some of the cases. Microscopically mesothelioma cells 
proliferated both on the parietal and visceral pleura and invaded into it. 
They proliferated in solitary, trabecular, papillary, or solid patterns in 
epithelioid mesothelioma. The lesions were discontinuous and multifo-
cal. Microscopic invasion into the lung and/or diaphragm was observed 
after evaluation of many blocks even in MPM with clinical stage I. 
Interlobar pleura and interlobular connective tissue was also invaded by 
the mesothelioma cells. The size of the lesion in the parietal pleura was 
larger than that in the visceral pleura. In an extremely early case, the 
lesions existed mainly in the parietal pleura, but a few foci of visceral 
pleural invasion were observed. Seeding of the mesothelioma cells on 
the tract of thoracoscopy was observed in three cases, and recurrence 
occurred in four of seven early stage MPMs. One-year and two-year 
overall survival rates for the early stage mesothelioma were 100% and 
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83.3%, respectively, and those for the advanced stage mesothelioma 
were 41.7% and 0%, respectively (p<0.0023).
Conclusions: Histopathologically, there were few cases with stage I 
mesothelioma. Invasion was observed even in extremely early stage 
MPMs in our series. Once MPM develops, mesothelioma cells may 
exfoliate easily into the pleural effusion or extend in lymphatic ves-
sels and disseminate diffusely onto the parietal and visceral pleura, 
thereafter proliferating as in situ neoplasm before invasive nodules are 
formed. Although MPM may ﬁrst develop at some point of parietal 
pleura, it soon invades into both parietal and visceral pleura, dissemi-
nates, proliferates and invades adjacent tissue rapidly. Because MPM 
with stage IA is rarely recognized, it is not practical to categorize stage 
I into stage IA or IB.
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Objective: Thymic carcinomas typically carry a poor prognosis and 
are quite rare. As such, their management has not been standardized. 
We reviewed our recent experience with multimodality treatment for 
thymic carcinoma for outcomes.
Methods: Retrospective review of a single institution surgical data-
base. Data included patient demographics, pre-operative staging and 
treatment, peri-operative events, pathologic ﬁndings, and postoperative 
outcomes.
Results: During the 10 year period from 1996-2006, 115 thymic 
tumors were primarily resected, including 17 patients who had WHO 
2004 Classiﬁcation thymic carcinoma. Patient characteristics are 
listed in the table below. At a mean follow-up of 28.4 months (range 
2.1-141.7, median 10.9), 59% (10/17) are disease-free, 2 have died 
of disease, 4 are alive with disease. Ten patients were able to undergo 
complete resections (59%). There was one operative mortality. There 
were no adverse events of CTCAE Grade III or higher. There have been 
no recurrences in those patients who had complete resections. Median 
survival has not yet been reached. 5-year survival is 80%.
Conclusion: Multimodality therapy in an attempt to attain complete 
resections for thymic carcinoma can result in good long-term survival.
Age (Years) 
Median 63
Range 25-73
Sex 
Male 12
Female 5
Preoperative Chemotherapy 12/17
Carboplatin/Docetaxel 5
Cyclophosphamide/Doxorubicin/Cisplatin 4
Cisplatin/Etoposide 2
Other 1
Additional Resected Structures 
Superior Vena Cava / Innominate Vein 5
Pneumonectomy 1
Postoperative Radiation 9/17
Median Dose (cGy) 5040
Range 3060-6300
Length of Stay (Days) 
Mean 5
Range 3-8
Histology 
Squamous 11
Lymphoepithelioma-like 3
Undiﬀerentiated 1
Mucoepidermoid 1
Adenocarcinoma 1
Masaoka Stage 
I 1
II 4
III 9
IV 3
P1-129 Mesothelioma and Other Thoracic Malignancy Posters, Mon, Sept 3 
The accuracy of pathological diagnosis of mesothelioma cases in 
Japan
Inai, Kouki1 Takeshima, Yukio1 Kishimoto, Takumi2 
1 Dept. of Pathology, Graduate School of Biomedical Sciences, 
Hiroshima University, Hiroshima, Japan 2 Okayama Rosai Hospital, 
Okayama, Japan 
Background: The malignant mesothelioma is increasing in Japan, due 
to the import and use of asbestos past 6 decades. However, its accurate 
frequency of mesothelioma is unknown due to different diagnostic 
methods and criteria. The aim of this study is to clarify the accuracy of 
pathological diagnosis of mesothelioma in Japan.
Materials and Methods: Among 878 mesothelioma death cases 
extracted by “Vital Statistics of Japan 2003”, the pathological materi-
als (histological and cytological specimens, parafﬁn blocks etc.) were 
submitted from 204 cases. After these pathological materials were 
